MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Annexon, Inc. - common stock (NQ:ANNX)

5.600 +0.220 (+4.09%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,704,231
Open 5.310
Bid (Size) 5.620 (700)
Ask (Size) 5.760 (100)
Prev. Close 5.380
Today's Range 5.250 - 5.635
52wk Range 1.285 - 7.180
Shares Outstanding 47,722,995
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy
From Annexon Biosciences
Via GlobeNewswire

Performance

YTD
+19.4%
+19.4%
1 Month
-14.1%
-14.1%
3 Month
+35.6%
+35.6%
6 Month
+170.5%
+170.5%
1 Year
+112.1%
+112.1%

More News

Read More
News headline image
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Monday? ↗
Via Chartmill
News headline image
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
News headline image
Which stocks are moving on Wednesday? ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Biosciences to Participate in Upcoming September Investor Conferences
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Narrows Loss in Fiscal Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy
From Annexon Biosciences
Via GlobeNewswire
News headline image
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
From Annexon Biosciences
Via GlobeNewswire

Frequently Asked Questions

Is Annexon, Inc. - common stock publicly traded?
Yes, Annexon, Inc. - common stock is publicly traded.
What exchange does Annexon, Inc. - common stock trade on?
Annexon, Inc. - common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Annexon, Inc. - common stock?
The ticker symbol for Annexon, Inc. - common stock is ANNX on the Nasdaq Stock Market
What is the current price of Annexon, Inc. - common stock?
The current price of Annexon, Inc. - common stock is 5.600
When was Annexon, Inc. - common stock last traded?
The last trade of Annexon, Inc. - common stock was at 02/27/26 04:00 PM ET
What is the market capitalization of Annexon, Inc. - common stock?
The market capitalization of Annexon, Inc. - common stock is 267.25M
How many shares of Annexon, Inc. - common stock are outstanding?
Annexon, Inc. - common stock has 267M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story